Emerging New Therapeutics for Retinoblastoma

Area of Science:

• Ophthalmology
• Oncology
• Molecular Biology

Background:

• Chemotherapy is the primary treatment for retinoblastoma, administered via intravenous, intra-arterial, or intravitreal routes.
• Current chemotherapy regimens exhibit significant ocular and systemic toxicities and are often associated with tumor recurrences due to resistant clones.

Purpose of the Study:

• To review the limitations of current retinoblastoma treatments.
• To explore novel therapeutic agents and molecular targets for retinoblastoma.
• To discuss future directions in retinoblastoma therapy.

Main Methods:

• Literature review of current and emerging retinoblastoma therapeutic strategies.
• Analysis of molecular drivers of retinoblastoma and mechanisms of therapeutic resistance.
• Evaluation of novel targeted drugs, including those targeting the MDMX-p53 pathway, histone deacetylase inhibitors, spleen tyrosine kinase inhibitors, and genetic/immune modulatory drugs.

Main Results:

• Chemotherapy for retinoblastoma presents challenges including toxicity and treatment resistance.
• Advances in understanding retinoblastoma molecular pathways enable the exploration of targeted therapies.
• Emerging agents show promise for improved bioavailability and reduced chemotoxicity.

Conclusions:

• Novel targeted drugs offer potential for more effective retinoblastoma treatment with fewer side effects.
• Further research into molecular pathways and targeted agents is crucial for advancing retinoblastoma therapy.
• Future therapeutic strategies aim for improved outcomes and reduced toxicity in retinoblastoma management.